Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents
- PMID: 17981675
- DOI: 10.2741/2807
Diagnostic and therapeutic application of telomerase-specific oncolytic adenoviral agents
Abstract
Replication-selective tumor-specific viruses present a novel approach for treatment of neoplastic disease. These vectors are designed to induce virus-mediated lysis of tumor cells after selective viral propagation within the tumor. Telomerase activation is considered to be a critical step in carcinogenesis and its activity correlates closely with human telomerase reverse transcriptase (hTERT) expression. Since only tumor cells that express telomerase activity would activate this promoter, the hTERT proximal promoter allows for preferential expression of viral genes in tumor cells, leading to selective viral replication. We constructed an attenuated adenovirus 5 vector (Telomelysin, OBP-301), in which the hTERT promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site (IRES). Telomelysin replicated efficiently and induced marked cell killing in a panel of human cancer cell lines, whereas replication as well as cytotoxicity was highly attenuated in normal human cells lacking telomerase activity. We further modified the E3 region of OBP-301 to contain green fluorescent protein (GFP) gene for monitoring viral replication (TelomeScan, OBP-401). When TelomeScan was intratumorally injected into human tumors orthotopically implanted into the rectum in mice, para-aortic lymph node metastasis could be visualized at laparotomy under a three-chip color cooled charged-coupled device camera. Our results indicate that TelomeScan causes viral spread into the regional lymphatic area and selectively replicates in neoplastic lesions, resulting in GFP expression in metastatic lymph nodes. This article reviews recent highlights in this rapidly evolving field: cancer therapeutic and cancer diagnostic approaches using the telomerase-specific oncolytic adenoviruses.
Similar articles
-
Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.Uirusu. 2008 Jun;58(1):11-8. doi: 10.2222/jsv.58.11. Uirusu. 2008. PMID: 19122384 Review.
-
[Theranostic application of telomerase-specific oncolytic adenovirus for human cancer].Nihon Rinsho. 2007 Oct;65(10):1913-22. Nihon Rinsho. 2007. PMID: 17926546 Review. Japanese.
-
[Oncolytic virotherapy for human solid tumors].Gan To Kagaku Ryoho. 2009 May;36(5):703-9. Gan To Kagaku Ryoho. 2009. PMID: 19461167 Review. Japanese.
-
Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter.Curr Cancer Drug Targets. 2007 Mar;7(2):191-201. doi: 10.2174/156800907780058835. Curr Cancer Drug Targets. 2007. PMID: 17346111 Review.
-
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.Exp Cell Res. 2006 Feb 1;312(3):256-65. doi: 10.1016/j.yexcr.2005.10.026. Epub 2005 Dec 13. Exp Cell Res. 2006. PMID: 16356494
Cited by
-
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.Mol Ther. 2010 Feb;18(2):429-34. doi: 10.1038/mt.2009.262. Epub 2009 Nov 24. Mol Ther. 2010. PMID: 19935775 Free PMC article. Clinical Trial.
-
Assessment of α-fetoprotein targeted HSV1-tk expression in hepatocellular carcinoma with in vivo imaging.Cancer Biother Radiopharm. 2015 Feb;30(1):8-15. doi: 10.1089/cbr.2014.1716. Epub 2014 Dec 29. Cancer Biother Radiopharm. 2015. PMID: 25545853 Free PMC article.
-
Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system.Sci Rep. 2017 Oct 26;7(1):14177. doi: 10.1038/s41598-017-14717-x. Sci Rep. 2017. PMID: 29074882 Free PMC article.
-
Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancer.Cancer Sci. 2009 Apr;100(4):678-83. doi: 10.1111/j.1349-7006.2009.01110.x. Epub 2009 Mar 1. Cancer Sci. 2009. PMID: 19298599 Free PMC article.